Marina Biotech (MRNA) Commences Enrollment in START-FAP Cohort 2

Marina Biotech, Inc. (Nasdaq: MRNA), has announced that Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508 will begin enrolling patients in the next several weeks at Massachusetts General Hospital (MGH) in Boston. The Company also noted that it has successfully transferred all GMP-related stability testing to a contract services organization.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
• Nymox Pharmaceutical (NYMX) Reports Statistically Significant Data for NX-1207 in BPH

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter